Cencora Inc (NYSE: COR) is a pharmaceutical distribution company that supplies pharmaceutical and related products to healthcare providers and supports pharmaceutical and biotech manufacturers across the drug supply chain. Revenue is generated primarily through product distribution markups and fees, with additional contributions from value-added services sold to both healthcare providers and pharmaceutical manufacturers. Cencora operates through a geographically diverse network of distribution service centers in the United States and select global markets, including the U.K. and the EU. Customers include pharmacies, health systems, medical and dialysis clinics, physicians, and veterinarians. The company also provides specialty pharmaceutical services and, as of January 2, 2025, acquired an 85% interest in Retina Consultants of America (RCA) for approximately $4.0 billion in cash, expanding its community provider relationships. Cencora describes itself as typically the primary supplier of pharmaceuticals to its healthcare provider customers, reflecting scale-based switching costs in its core distribution business.

Revenue model

Revenue is generated primarily through pharmaceutical product distribution, where Cencora earns the spread between acquisition cost and selling price. Supplementary revenue comes from value-added services sold to healthcare providers and pharmaceutical and biotech manufacturers, including services supporting clinical development and commercialization of therapies.

Products and services

Core offerings include pharmaceutical distribution through a network of distribution service centers. Additional services include cold chain storage and shipping, specialty pharmaceutical support for manufacturers, clinical development and commercialization services, and, following the January 2, 2025 acquisition of RCA, management services for retina specialists. The company also holds a 34.9% interest (acquired June 2023 for $718.4 million) in a joint venture owning OneOncology, a network of oncology practices.

Customers and end markets

Customers include healthcare providers (pharmacies, health systems, medical and dialysis clinics, physicians, veterinarians) and pharmaceutical and biotech manufacturers. End markets are driven by U.S. pharmaceutical sales growth, an aging population, and introduction of new pharmaceuticals including biologics and gene therapies. U.S. pharmaceutical sales are estimated by IQVIA to grow at approximately 8.4% compound annual growth rate from 2024 through 2029, per the fiscal 2025 10-K.

Value-chain role

Cencora sits between pharmaceutical manufacturers and end-point healthcare providers, functioning as a wholesale distributor and primary pharmaceutical supplier. It also provides upstream services to manufacturers (commercialization, clinical development support) and downstream services to providers (efficiency and operational support), positioning it as a mid-chain intermediary with service extensions at both ends.

Geographic exposure

Operations are concentrated in the United States, with additional distribution centers and facilities in the U.K., the EU, and other global markets including China, India, Turkey, and other countries, per the fiscal 2025 10-K.

Source: SEC 10-K, filed 2025-11-25

Industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries Peers: Adapthealth Corp Cardinal Health Inc COVETRUS, INC. Henry Schein Inc McKesson Corp PATTERSON COMPANIES, INC. Accendra Health Inc PetIQ, Inc.